The name of the issuer is BioNTech SE (the “Company”).
Item 1(b) | Address of Issuer’s Principal Executive Offices. |
The Company’s principal executive office is located at An der Goldgrube 12,D-55131 Mainz, Germany.
Item 2(a) | Name of Person Filing. |
This Schedule 13G is being jointly filed by ATHOS KG, AT Impf GmbH, Helmut Jeggle and Thomas Maier, each of the foregoing, a “Reporting Person,” and collectively, the “Reporting Persons”. The sole member of AT Impf GmbH is ATHOS KG and, as a result, ATHOS KG is deemed to be the beneficial owner of the securities held by AT Impf GmbH. Helmut Jeggle and Thomas Maier are each general partners (komplementär)of ATHOS KG. The limited partners (kommanditisten) of ATHOS KG are members of the families of Thomas and Andreas Str��ngmann.
The Reporting Persons have entered into a Joint Filing Agreement, dated February 12, 2020, a copy of which is incorporated by reference herein to Exhibit on the Schedule 13G filed on February 12, 2020, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule13d-1(k)(1) under the Act.
Item 2(b) | Address of Principal Business Office or, if none, Residence. |
The address of the principal business office of each of the Reporting Persons is Bergfeldstraße 9 83607 Holzkirchen.
ATHOS KG is a German limited partnership (Kommanditgesellschaft); AT Impf GmbH is a German limited liability company (Gesellschaft mit beschränkter Haftung); and Mr. Jeggle and Mr. Maier are each citizens of Germany.
Item 2(d) | Title of Class of Securities. |
Ordinary Shares, no par value per share (€1.00 nominal amount)
09075V102 (This CUSIP number applies to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol “BNTX.” Each ADS represents one Ordinary Share. No CUSIP has been assigned to the Ordinary Shares.)
Item 3 | If this statement is filed pursuant to Rules13d-1(b), or13d-2(b), check whether the person filing is a: |
Not applicable.
Provide the following information regarding the aggregate number and percentage of the class of securities of the
issuer identified in Item 1.
| (a) | Amount beneficially owned: |
6